Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|E4599||ECOG||Randomized Phase II/III Trial of Paclitaxel plus Carboplatin With or Without Bevacizumab (NSC #704865) in Patients with Advanced Nonsquamous NSCLC||Adult CIRB - Late Phase Emphasis||Completed|
|CALGB-90104||CALGB||A Randomized Phase III Study Comparing Sequential Chemotherapy (AG-TP) to Cisplatin and Gemcitabine as Adjuvant Treatment After Cystectomy for Transitional Cell Carcinoma of the Bladder||Adult CIRB - Late Phase Emphasis||Completed|
|S0012||SWOG||A Comparative Randomized Study of Standard Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Vs. Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF Followed by Weekly Paclitaxel as Neoadjuvant Therapy for Inflammatory and Locally Advanced Breast Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|RTOG-0525||RTOG||Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-Intensive Temozolomide in Patients with Newly Diagnosed Glioblastoma||Adult CIRB - Late Phase Emphasis||Completed|
|NSABP-B-38||NSABP||A Phase III; Adjuvant Trial Comparing Three Chemotherapy Regimens in Women with Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed by DD Paclitaxel (DD AC->P); DD AC Followed by DD Paclitaxel Plus Gemcitabine (DD AC->PG)||Adult CIRB - Late Phase Emphasis||Completed|
|AALL05B1||COG||A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens||Pediatric CIRB||Completed|
|NSABP-C-08||NSABP||A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU); Leucovorin; and Oxaliplatin (mFOLFOX6) Every Two Weeks with Bevacizumab to the Same Regimen without Bevacizumab for the Treatment of Patients with Resected Stages II and III Carcinoma of the Colon||Adult CIRB - Late Phase Emphasis||Completed|
|GOG-0240||GOG||A Randomized Phase III Trial of Cisplatin plus Paclitaxel with and without NCI-Supplied Bevacizumab (NSC #704865; IND #113912) Versus the Non-Platinum Doublet; Topotecan Plus Paclitaxel; with and without NCI-Supplied Bevacizumab; in Stage IVB; Recurrent or Persistent Carcinoma of the Cervix||Adult CIRB - Late Phase Emphasis||Completed|
|ACNS0621||COG||Cilengitide (EMD 121974) (IND# 59073) in Recurrent or Progressive and Refractory Childhood High-Grade Glioma: A Groupwide Phase II Study||Pediatric CIRB||Completed|
|CALGB-70301||CALGB||Quality of Life; Employment; and Informal Care Cost Analysis in Women Receiving Adjuvant Chemotherapy for Breast Cancer with 0-3 Positive Axillary Lymph Nodes: Companion to CALGB 40101||Adult CIRB - Late Phase Emphasis||Completed|